Great news on progress for a COVID-19 vaccine from Pfizer. From their press release:
- Vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection in the first interim efficacy analysis
- Analysis evaluated 94 confirmed cases of COVID-19 in trial participants
- Study enrolled 43,538 participants, with 42% having diverse backgrounds, and no serious safety concerns have been observed; Safety and additional efficacy data continue to be collected
- Submission for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) planned for soon after the required safety milestone is achieved, which is currently expected to occur in the third week of November
The Phase 3 clinical trial of BNT162b2 began on July 27. Pfizer expects to produce o produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses in 2021. Note that since this is a two-dose regimen, this would be sufficient capacity for 25 million people this year and 650 million people next year.